

**WEST****Freeform Search****Database:**

US Patents Full-Text Database  
JPO Abstracts Database  
EPO Abstracts Database  
Derwent World Patents Index  
IBM Technical Disclosure Bulletins

**Term:**

patient same l1 same mixture

**Display:**  **Documents in Display Format:**  **Starting with Number** **Generate:** ☐ Hit List ☒ Hit Count ☐ Image

Search

Clear

Help

Logout

Interrupt

Main Menu

Show S Numbers

Edit S Numbers

Preferences

**Search History****Today's Date:** 1/17/2001

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,JPAB,EPAB,DWPI,TDBD	patient same l1 same mixture	15	<u>L2</u>
USPT,JPAB,EPAB,DWPI,TDBD	ozone same oxygen	11749	<u>L1</u>

**WEST**

Generate Collection

L2: Entry 8 of 15

File: JPAB

Apr 4, 1995

PUB-NO: JP407087965A

DOCUMENT-IDENTIFIER: JP 07087965 A

TITLE: PRODUCTION OF CELL CULTURE WITH ELEVATED CONTENT OF ENDOGENOUS CYTOKINE

PUBN-DATE: April 4, 1995

## INVENTOR-INFORMATION:

NAME

COUNTRY

KIEF, HORST

N/A

## ASSIGNEE-INFORMATION:

NAME

COUNTRY

KIEF HORST

N/A

APPL-NO: JP05352187

APPL-DATE: December 28, 1993

INT-CL (IPC): C12N 5/06; C12P 21/00; A61K 38/00; A61K 38/21

## ABSTRACT:

PURPOSE: To produce an endogenous cytokine having great permissibility in a high yield at a low cost.

CONSTITUTION: This method for producing a cell culture comprises culturing the cell culture in a usual fashion and adding a lysate obtained by ozonolysis and proteolysis from blood or a blood fraction and/or urine as a stimulant in a method for producing the cell culture with an increased content of an endogenous cytokine comprising treating a patient's own blood with an ozone-oxygen mixture and fractionating the treated mixture.

COPYRIGHT: (C)1995, JPO

**WEST**

Generate Collection

L2: Entry 7 of 15

File: USPT

Oct 1, 1991

DOCUMENT-IDENTIFIER: US 5052382 A

TITLE: Apparatus for the controlled generation and administration of ozone

CLPR:

3. Apparatus according to claim 1 wherein the output means is for treating a patient's blood, said output means comprising a dose discharge syringe means which is driven by a stepper motor for discharging controlled doses of a mixture of oxygen and ozone for the patient's blood, and a purge means for purging the blood treating means with the mixture of ozone and oxygen prior to treating the patient's blood.

**WEST****End of Result Set**

Generate Collection

L2: Entry 15 of 15

File: DWPI

Oct 20, 1988

DERWENT-ACC-NO: 1988-300491

DERWENT-WEEK: 198843

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Injection of anticoagulant into blood - involves capsule attached to flexible hose connected to cannula to withdraw blood from patient

INVENTOR: GRIESEL, H

PATENT-ASSIGNEE:

ASSIGNEE

CODE

GRIESEL H

GRIEI

PRIORITY-DATA: 1987DE-3710998 (April 1, 1987)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 3710998 A	October 20, 1988	N/A	003	N/A

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
DE 3710998A	April 1, 1987	1987DE-3710998	N/A

INT-CL (IPC): A61M 1/02

ABSTRACTED-PUB-NO: DE 3710998A

BASIC-ABSTRACT:

The appts. is used for treating a patient by the ozone therapy method. Blood is removed from the patient by inserting a cannula into the cubital vein and connecting the cannula by a flexible tube to a bottle. An anticoagulant is mixed with the blood in a defined proportion and a defined quantity of an ozone-oxygen mixture is added to the blood before the blood is returned to the patient.

The method of adding the anticoagulant involves a capsule (11) which contains a defined quantity of the anticoagulant. The outlet (12) from the capsule is pressed through the wall of a flexible hose (2) near to its junction with the cannula (1). The anti-coagulant is pressed out of the capsule (11) by a device (13) actuated by a thumb screw (15).

USE - Adding an anticoagulant to blood during therapy in which blood is removed from the body via a cannula.

CHOSEN-DRAWING: Dwg.2/2

TITLE-TERMS: INJECTION ANTICOAGULANT BLOOD CAPSULE ATTACH FLEXIBLE HOSE CONNECT CANNULA WITHDRAW BLOOD PATIENT

DERWENT-CLASS: P34

SECONDARY-ACC-NO:

Non-CPI Secondary Accession Numbers: N1988-228036

**WEST**☐ Generate Collection

L2: Entry 13 of 15

File: DWPI

Dec 20, 1997

DERWENT-ACC-NO: 1998-375521

DERWENT-WEEK: 199832

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: A method of treating neuro-dermatitis - by rectal introduction of an oxygen-ozone mixture and intramuscular injection of auto-blood saturated with oxygen-ozone mixture

INVENTOR: GLAVINSKAYA, T A; IVANOVA, O A

PATENT-ASSIGNEE:

ASSIGNEE

NIZHEGOROD MED INST

NIZHEGOROD SKIN VENERAL RES INST

CODE

NIZHR

NIZHR

PRIORITY-DATA: 1994RU-0026137 (July 14, 1994)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
RU 2099061 C1	December 20, 1997	N/A	004	A61K033/00

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
RU 2099061C1	July 14, 1994	1994RU-0026137	N/A

INT-CL (IPC): A61K 33/00; A61M 1/14; A61M 1/32

ABSTRACTED-PUB-NO: RU 2099061C

BASIC-ABSTRACT:

A method of treating neuro-dermatitis by rectal introduction of an oxygen-ozone mixture (OOM) is new. The mixture contains 50 mu g ozone/litre of mixture. The mixture is introduced once daily in 400 cm<sup>3</sup> volume over 18 days, with a daily increase of the volume introduced to 100 cm<sup>3</sup> per day. The patient is also subjected to a daily i.m. injection of auto-blood, saturated with 15 cm<sup>3</sup> of OOM, ozone concentration 50 mu g ozone/litre of mixture, twice per week, up to 10 injections.

ADVANTAGES - The method is more effective than previous methods and reduces complications.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: METHOD TREAT NEURO DERMATITIS RECTUM INTRODUCING OXYGEN OZONE MIXTURE INTRAMUSCULAR INJECTION AUTO BLOOD SATURATE OXYGEN OZONE MIXTURE

DERWENT-CLASS: B06 P34

CPI-CODES: B04-B04D5; B05-C08; B14-N17C;

## CHEMICAL-CODES:

Chemical Indexing M1 \*01\*

Fragmentation Code

M423 M431 M782 M903 P943 V600 V615

Chemical Indexing M2 \*02\*

Fragmentation Code

C108 C550 C810 M411 M431 M782 M903 M904 M910 P943

Specific Compounds

01779M

Registry Numbers

1779U

Chemical Indexing M2 \*03\*

Fragmentation Code

C408 C550 C810 M411 M431 M782 M903 M904 M910 P943

Specific Compounds

01887M

Registry Numbers

1887U

UNLINKED-DERWENT-REGISTRY-NUMBERS: 1779U; 1887U

## SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1998-113835

Non-CPI Secondary Accession Numbers: N1998-293627

**WEST**

Generate Collection

L2: Entry 10 of 15

File: DWPI

Sep 20, 1999

DERWENT-ACC-NO: 2000-462870

DERWENT-WEEK: 200040

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Method of treatment of patients with malignant neoplasms in experiment

INVENTOR: KONTORSHCHIKOVA, K N; SHCHERBATYUK, T G

PATENT-ASSIGNEE:

ASSIGNEE

CODE

NIZHEGOROD MED ACAD

NIZHR

SHCHERBATYUK T G

SHCHI

PRIORITY-DATA: 1996RU-0124167 (December 24, 1996)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
RU 2137481 C1	September 20, 1999	N/A	000	A61K033/00

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
RU 2137481C1	December 24, 1996	1996RU-0124167	N/A

INT-CL (IPC): A61K 33/00; A61K 33/14

ABSTRACTED-PUB-NO: RU 2137481C

BASIC-ABSTRACT:

NOVELTY - Invention proposes to use a physiological solution obtained by bubbling with ozone-oxygen mixture at the rate of gas flow 0.5-1 l/min for 15-20 min at ozone concentration in gaseous mixture 800-5 000 mcg/l. Solution is administrated into tumor directly by perimeter of its localization at volume 0.5-1.5 ml. Invention can be used for validity of the following study and using the ozonotherapy for treatment of patients with malignant neoplasms.

USE - Medicine, experimental oncology.

ADVANTAGE - Broadened arsenal of treatment methods. 5 tbl, 3 ex

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: METHOD TREAT PATIENT MALIGNANT NEOPLASMS EXPERIMENT

DERWENT-CLASS: B06

CPI-CODES: B05-C08; B14-H01B;

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C2000-139394



**WEST**

Generate Collection

L2: Entry 9 of 15

File: EPAB

Jul 28, 1992

PUB-NO: US005133975A

DOCUMENT-IDENTIFIER: US 5133975 A

TITLE: Method for in vivo inactivation of blood borne HIV virus using a mixture of ozone and oxygen

PUBN-DATE: July 28, 1992

## INVENTOR-INFORMATION:

NAME

COUNTRY

HARLEY, RICHARD J

US

BIMBI, PETER

US

GREENE, DON

US

WAINWRIGHT, BASIL

US

## ASSIGNEE-INFORMATION:

NAME

COUNTRY

RJH AND COMPANY INC

US

APPL-NO: US39435689

APPL-DATE: August 15, 1989

## PRIORITY-DATA:

INT-CL (IPC): A61K 33/40

EUR-CL (EPC): A61K033/40

## ABSTRACT:

The invention discloses a method for inactivating infectious agents in a patient's blood in vivo. The method involves administering to the patient a non-toxic, infectious agent inactivating amount of a mixture of oxygen and ozone. The mixture is preferably administered via rectal insufflation or via autohemotherapy.

**WEST**

Generate Collection

L2: Entry 3 of 15

File: USPT

Feb 22, 2000

DOCUMENT-IDENTIFIER: US 6027688 A

TITLE: Apparatus and method for inactivation of human immunodeficiency virus

## BSPR:

The invention is particularly adapted for the extra-corporeal treatment of human blood in a continuous process, wherein blood is withdrawn from a patient, circulated through the treatment apparatus of the invention and returned to the patient. Although the specific conditions of the treatment process may vary from patient to patient, depending upon the general health of the patient and the condition of the blood, satisfactory results are generally obtained when the blood is caused to flow through the gas-liquid contact apparatus at a flow rate of about 65 ml/min, typically achieved when the gas-liquid contact apparatus is inclined at an angle of about 27.degree. to the horizontal, and the concentration of ozone in the ozone-oxygen mixture is no more than about 27 .mu.g/ml and is at a surface pressure of about 2.2 psig.

**WEST**

Generate Collection

L2: Entry 14 of 15

File: DWPI

Oct 12, 2000

DERWENT-ACC-NO: 1994-236472

DERWENT-WEEK: 200052

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Recovery of cell cultures with increased content of cytokine(s) -  
comprises gassing the patient's own blood with an ozone/oxygen mixt. and  
fractionating and conventional cell culture using lysates as stimulants

INVENTOR: KIEF, H

PATENT-ASSIGNEE:

ASSIGNEE

CODE

KIEF H

KIEFI

KEEF H

KEEFI

PRIORITY-DATA: 1992DE-4244437 (December 29, 1992)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 59310100 G	October 12, 2000	N/A	000	A61K035/14
EP 607593 A2	July 27, 1994	G	003	A61K035/14
DE 4244437 A1	July 28, 1994	N/A	003	C12P021/00
AU 9352790 A	July 14, 1994	N/A	000	C12N005/00
CA 2112314 A	June 30, 1994	N/A	000	C12N005/02
ZA 9309718 A	October 26, 1994	N/A	008	C12P000/00
JP 07087965 A	April 4, 1995	N/A	003	C12N005/06
EP 607593 A3	December 14, 1994	N/A	000	A61K035/14
AU 672449 B	October 3, 1996	N/A	000	C12N005/00
EP 607593 B1	September 6, 2000	G	000	A61K035/14

DESIGNATED-STATES: AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE AT BE CH DE  
DK ES FR GB GR IE IT LI LU NL PT SE

CITED-DOCUMENTS: No-SR.Pub; 2.Jnl.Ref ; EP 265548

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
DE 59310100G	December 20, 1993	1993DE-0510100	N/A
DE 59310100G	December 20, 1993	1993EP-0120536	N/A
DE 59310100G		EP 607593	Based on
EP 607593A2	December 20, 1993	1993EP-0120536	N/A
DE 4244437A1	December 29, 1992	1992DE-4244437	N/A
AU 9352790A	December 24, 1993	1993AU-0052790	N/A
CA 2112314A	December 23, 1993	1993CA-2112314	N/A
ZA 9309718A	December 28, 1993	1993ZA-0009718	N/A
JP 07087965A	December 28, 1993	1993JP-0352187	N/A
EP 607593A3	December 20, 1993	1993EP-0120536	N/A
AU 672449B	December 24, 1993	1993AU-0052790	N/A
AU 672449B		AU 9352790	Previous Publ.
EP 607593B1	December 20, 1993	1993EP-0120536	N/A

INT-CL (IPC): A61K 35/14; A61K 37/02; A61K 37/66; A61K 38/00; A61K 38/21; C12N 5/00; C12N 5/02; C12N 5/06; C12N 5/08; C12P 0/00; C12P 21/00; C12P 21/00; C12R 1/91

ABSTRACTED-PUB-NO: EP 607593A

BASIC-ABSTRACT:

Recovering cell cultures with an increased content of the body's own cytokines comprises gassing blood cultures from the patient with an ozone, oxygen mixt. and fractionating comprising cultivating the cell cultures in known manner and adding lysates as stimulants, these lysates having been obtd. by ozonolysis and proteolysis of blood or blood fractions and/or urine.

The cell cultures are full blood, leucocytes, lymphocytes or mixed cultures.

USE/ADVANTAGE - The process can be used to obtain cytokines from the patient's own body, which (on account of their origin) can be given back to the same organism and are better tolerated in that they have been left in the body's own medium. The cytokines are obtd. more cheaply than previously and are better tolerated by the patient's body. Yields are higher than in previous processes.

ABSTRACTED-PUB-NO:

EP 607593B

EQUIVALENT-ABSTRACTS:

Recovering cell cultures with an increased content of the body's own cytokines comprises gassing blood cultures from the patient with an ozone, oxygen mixt. and fractionating comprising cultivating the cell cultures in known manner and adding lysates as stimulants, these lysates having been obtd. by ozonolysis and proteolysis of blood or blood fractions and/or urine.

The cell cultures are full blood, leucocytes, lymphocytes or mixed cultures.

USE/ADVANTAGE - The process can be used to obtain cytokines from the patient's own body, which (on account of their origin) can be given back to the same organism and are better tolerated in that they have been left in the body's own medium. The cytokines are obtd. more cheaply than previously and are better tolerated by the patient's body. Yields are higher than in previous processes.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: RECOVER CELL CULTURE INCREASE CONTENT CYTOKINE COMPRISE GAS  
PATIENT BLOOD OZONE OXYGEN MIXTURE FRACTIONATE CONVENTION CELL CULTURE LYSATE

STIMULATING

DERWENT-CLASS: B04 D16

CPI-CODES: B04-J01; D05-H08; D05-H13;

CHEMICAL-CODES:

Chemical Indexing M1 \*01\*

Fragmentation Code

M423 M720 M903 N161 N511 N512 N513 Q233 V752 V753

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1994-107539